Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2017 Aug 01;922:151-161. doi: 10.1124/mol.117.108944.
Show Gene links
Show Anatomy links
Identification of AICP as a GluN2C-Selective N-Methyl-d-Aspartate Receptor Superagonist at the GluN1 Glycine Site.
Jessen M
,
Frederiksen K
,
Yi F
,
Clausen RP
,
Hansen KB
,
Bräuner-Osborne H
,
Kilburn P
,
Damholt A
.
???displayArticle.abstract???
N-methyl-d-aspartate (NMDA)-type ionotropic glutamate receptors mediate excitatory neurotransmission in the central nervous system and are critically involved in brain function. NMDA receptors are also implicated in psychiatric and neurological disorders and have received considerable attention as therapeutic targets. In this regard, administration of d-cycloserine (DCS), which is a glycine site NMDA receptor agonist, can enhance extinction of conditioned fear responses. The intriguing behavioral effects of DCS have been linked to its unique pharmacological profile among NMDA receptor subtypes (GluN1/2A-D), in which DCS is a superagonist at GluN2C-containing receptors compared with glycine and a partial agonist at GluN2B-containing receptors. Here, we identify (R)-2-amino-3-(4-(2-ethylphenyl)-1H-indole-2-carboxamido)propanoic acid (AICP) as a glycine site agonist with unique GluN2-dependent differences in agonist efficacy at recombinant NMDA receptor subtypes. AICP is a full agonist at GluN1/2A (100% response compared with glycine), a partial agonist at GluN1/2B and GluN1/2D (10% and 27%, respectively), and a highly efficacious superagonist at GluN1/2C receptors (353%). Furthermore, AICP potencies are enhanced compared with DCS with EC50 values in the low nanomolar range (1.7 nM at GluN1/2C). We show that GluN1/2C superagonism of AICP and DCS is mediated by overlapping but distinct mechanisms and that AICP selectively enhances responses from recombinant GluN1/2C receptors in the presence of physiological glycine concentrations. This functional selectivity of AICP for GluN2C-containing NMDA receptors is more pronounced compared with DCS, suggesting that AICP can be a useful tool compound for uncovering the roles of GluN2C subunits in neuronal circuit function and in the development of new therapeutic strategies.
,
Correction to "Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site".
2018, Pubmed
,
Correction to "Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site".
2018,
Pubmed
Balu,
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
2015,
Pubmed
Banke,
Activation of NR1/NR2B NMDA receptors.
2003,
Pubmed
Benveniste,
Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine.
1991,
Pubmed
Bergeron,
Modulation of N-methyl-D-aspartate receptor function by glycine transport.
1998,
Pubmed
Billups,
Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse.
2003,
Pubmed
Chen,
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.
2008,
Pubmed
,
Xenbase
Clements,
Kinetics of AP5 dissociation from NMDA receptors: evidence for two identical cooperative binding sites.
1994,
Pubmed
Davis,
Effects of D-cycloserine on extinction: translation from preclinical to clinical work.
2006,
Pubmed
Dravid,
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.
2010,
Pubmed
,
Xenbase
Dutta,
Ketamine and other potential glutamate antidepressants.
2015,
Pubmed
Flood,
Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor.
1992,
Pubmed
Gielen,
Mechanism of differential control of NMDA receptor activity by NR2 subunits.
2009,
Pubmed
Goff,
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
2015,
Pubmed
Gupta,
Effect of D-cycloserine in conjunction with fear extinction training on extracellular signal-regulated kinase activation in the medial prefrontal cortex and amygdala in rat.
2013,
Pubmed
Hansen,
Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Henderson,
Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor.
1990,
Pubmed
Hillman,
Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory.
2011,
Pubmed
Hofmann,
D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.
2015,
Pubmed
Johnson,
Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons.
1992,
Pubmed
Karakas,
Crystal structure of a heterotetrameric NMDA receptor ion channel.
2014,
Pubmed
Kenakin,
The pharmacological classification of practolol and chloropractolol.
1978,
Pubmed
Khatri,
Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.
2014,
Pubmed
,
Xenbase
Kussius,
Kinetic basis of partial agonism at NMDA receptors.
2009,
Pubmed
Kvist,
Structure-based discovery of antagonists for GluN3-containing N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Lench,
Differential Effects of D-Cycloserine and ACBC at NMDA Receptors in the Rat Entorhinal Cortex Are Related to Efficacy at the Co-Agonist Binding Site.
2015,
Pubmed
McBain,
Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
1989,
Pubmed
,
Xenbase
Menniti,
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
2013,
Pubmed
Monahan,
D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats.
1989,
Pubmed
Mullasseril,
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.
2010,
Pubmed
Ogden,
Contribution of the M1 transmembrane helix and pre-M1 region to positive allosteric modulation and gating of N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Ogden,
Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice.
2014,
Pubmed
,
Xenbase
Ogden,
New advances in NMDA receptor pharmacology.
2011,
Pubmed
Otto,
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.
2016,
Pubmed
Paoletti,
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
2013,
Pubmed
Priestley,
Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex.
1994,
Pubmed
Pérez-Otaño,
Emerging roles of GluN3-containing NMDA receptors in the CNS.
2016,
Pubmed
Ressler,
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
2004,
Pubmed
Schade,
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
2016,
Pubmed
Schuster,
D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task.
1992,
Pubmed
Sheinin,
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine.
2001,
Pubmed
,
Xenbase
Skolnick,
Glutamate-based antidepressants: 20 years on.
2009,
Pubmed
Strong,
NMDA receptor modulators: an updated patent review (2013-2014).
2014,
Pubmed
Szakacs,
The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
2012,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Urwyler,
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
2009,
Pubmed
Walker,
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.
2002,
Pubmed
Watson,
D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.
1990,
Pubmed
,
Xenbase
Yang,
Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
2008,
Pubmed
Yi,
Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors.
2016,
Pubmed
,
Xenbase
Yuan,
Control of NMDA receptor function by the NR2 subunit amino-terminal domain.
2009,
Pubmed
,
Xenbase
Zarate,
New paradigms for treatment-resistant depression.
2013,
Pubmed